Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lab Professionals Oppose Draft Dx Reform Bill; Lab, IVD Industry Ready To Work With Congress

Executive Summary

The clinical lab industry and IVD test-kit-makers appear ready to work with lawmakers on diagnostic reforms that would create a new category of regulated product for all lab tests that would undergo a mix of US FDA and CMS oversight. Meanwhile, key groups representing laboratory professionals remain fundamentally opposed to the concept.

Advertisement

Related Content

Clinical Labs Find Fault In FDA Dx Reform Ideas, But Kit-Makers Signal General Approval
Medtech's Unfinished Business For Congress In 2018: What's Ahead
US FDA Chief Favors LDT Approach In Bucshon-DeGette Bill
Market Intel: Voyage Into Point-Of-Care Testing Gets Deeper
US Congress 'May' Finish Diagnostic Regulatory Reforms By End Of 2017, Rep. Burgess Says
Will Senate User-Fee Package Be Smooth Sailing Despite Add-Ons?
US FDA Gains Budget Increase In FY 2017…And Not Through Fees
Diagnostics Reg Overhaul Floated In US House
FDA Passes The Buck On LDTs, But Floats Ideas
Senators Circulate Plan For Standalone FDA Diagnostics Center, ‘In Vitro Clinical Test’ Rules

Topics

Advertisement
UsernamePublicRestriction

Register

MT104722

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel